Novo Nordisk India and Emcure Pharma have announced a partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.

Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity. In clinical trials, one in three participants on Wegovy experienced weight loss of over 20 percent. Poviztra is a second brand of Wegovy.

This partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, semaglutide injection 2.4 mg, in India.

Commenting on the partnership, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, said, “Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment. This partnership brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s robust marketing and distribution capabilities to improve access to obesity treatment for people living with overweight or obesity in India.”